Takara Bio PrimeCap T7 RNA Polymerase

Takara Bio has launched the PrimeCap T7 RNA Polymerase, a mutant T7 RNA polymerase designed for mRNA therapeutic research and development. According to Takara, PrimeCap T7 RNA Polymerase has been genetically engineered to maintain high-performance RNA synthesis activity while reducing dsRNA production to less than 10 percent. Additional genetic modifications have resulted in a fourfold reduction of cap analog concentration in the IVT reaction while maintaining a capping efficiency above 95 percent, the company said. The enzyme is currently available in research grade, but the company said it plans to soon release a GMP version of the enzyme.